Semaglutide vs Ipamorelin: Head-to-Head Comparison
Semaglutide is an FDA-approved GLP-1 agonist for direct weight loss, while ipamorelin is a GH secretagogue that can improve body composition through increased growth hormone. Semaglutide produces dramatically more weight loss, but ipamorelin may support lean mass retention and recovery.
Side-by-Side Comparison
| Dimension | Semaglutide | Ipamorelin |
|---|---|---|
| Evidence Level | Phase III trials, FDA-approved | Phase II trials; no FDA approval |
| FDA Status | FDA-approved (Ozempic/Wegovy) | Not approved |
| Mechanism | GLP-1 receptor agonist | Ghrelin receptor agonist (GH secretagogue) |
| Weight Loss Efficacy | 15-17% body weight in clinical trials | Indirect; improved body composition via GH, not direct weight loss |
| Side Effects | GI effects, potential thyroid/pancreatitis concerns | Minimal; clean side-effect profile |
| Muscle Impact | Lean mass loss of 25-40% of total weight lost | GH elevation may support lean mass |
| Cost | Very high (branded) | Moderate (research peptide) |
Peptide Overviews
Semaglutide
AFDA ApprovedSemaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). One of the most studied peptide drugs in recent history.
Ipamorelin
BHuman StudiesIpamorelin is a selective growth hormone secretagogue that stimulates growth hormone release from the pituitary gland without significantly affecting cortisol or prolactin levels.
Semaglutide vs Ipamorelin: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.